Sareum Holdings PLC Preclinical Data for SRA737 in Ovarian Cancer (4818H)
15 November 2018 - 9:24PM
UK Regulatory
TIDMSAR
RNS Number : 4818H
Sareum Holdings PLC
15 November 2018
(AIM: SAR) 15 November 2018
Sareum Holdings plc
("Sareum" or "the Company")
Sierra Oncology Reports Supportive Preclinical Data for SRA737
in Ovarian Cancer Models
Sareum Holdings plc (AIM: SAR), the specialist small molecule
drug development business, notes that Sierra Oncology, the licence
holder advancing clinical cancer candidate SRA737, has today
reported new preclinical data that support its ongoing clinical
trial with SRA737 as a monotherapy in ovarian cancer. The data were
presented in a poster at the 30(th) EORTC-NCI-AACR Symposium
currently being held in Dublin, Ireland.
As reported in the poster:
-- Chk1 inhibition by SRA737 shows promising efficacy in
CCNE1-amplified and MYCN overexpressing preclinical models of
high-grade serous ovarian cancer (HGSOC)
-- The in vivo data support the ongoing monotherapy clinical
trial of SRA737, which includes the prospective enrolment of
patients with these HGSOC subtypes
-- Furthermore, the preclinical data suggest that the
exploration of potential combination regimens with other compounds,
such as low dose gemcitabine and PARP inhibitors, is warranted for
HGSOC
Dr Tim Mitchell, CEO of Sareum Holdings plc, said: "The data
presented today continue to provide evidence that SRA737 has
potential in ovarian cancer where the tumours exhibit defective
cell cycle checkpoint control and replicative stress, and which is
identifiable by genetic markers. This represents a significant
proportion of HGSOC patients who currently have few treatment
options. We are encouraged by the new data, which supports the
rationale for Sierra's clinical study with SRA737 as a monotherapy,
and look forward to updates from the ongoing clinical trials in the
first half of 2019."
Title: SRA737, a novel Chk1 inhibitor, shows efficacy in
CCNE1-amplified and MYCN-overexpressing high-grade serous ovarian
cancer patient-derived xenograft models
Authors: G.Y. Ho, et al.
The full announcement by Sierra Oncology can be found by
clicking here
A copy of poster can be found here:
http://investor.sierraoncology.com/publications
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Nominated Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David
Dible 020 7282 9571
Notes for editors:
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics, to improve the treatment of
cancer and autoimmune disease. The Company generates value through
licensing its candidates to international pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum's leading clinical-stage programme, SRA737, a novel
Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed
Sierra Oncology, is in Phase 2 clinical trials targeting ovarian
and other advanced cancers. The key role of Chk1 in cancer cell
replication and DNA damage repair suggests that SRA737 may have
broad application as a targeted therapy in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
Sareum is also advancing internal programmes focused on distinct
dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors
through preclinical development as therapies for autoimmune
diseases and cancers. TYK2 and JAK1 have roles in pro-inflammatory
responses in autoimmune diseases (e.g. psoriasis, rheumatoid
arthritis, inflammatory bowel diseases and lupus) and tumour cell
proliferation in certain cancers (e.g. T-cell acute lymphoblastic
leukaemia and some solid tumours). The Company is targeting first
human clinical trials in each indication in 2020.
The Company also has an Aurora+FLT3 inhibitor targeting
haematological cancers, which is at the preclinical development
stage.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESLLFFILILELIT
(END) Dow Jones Newswires
November 15, 2018 05:24 ET (10:24 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024